Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Vivione Biosciences Inc. Receives AOAC Certification, Positions Brand for Fast Growth in Food Industry

V.VBI

Vivione Biosciences Inc. (“Vivione”) (TSXV:VBI), through its wholly owned subsidiary Vivione Biosciences, LLC, is proud to announce that it has received AOAC (Association of Analytical Communities) certification for its E. coli O157 and Non O157 STEC diagnostic tests for the RAPID-B platform. This is Vivione’s first AOAC certification for its RAPID-B platform, whose technology has the ability to accurately detect a contamination issue in seven hours or less.

“We are extremely pleased to have been awarded this globally recognized certification,” said Kevin Kuykendall, CEO of Vivione. “Our technology is one of the fastest diagnostic tests on the market for E-coli O157 and Non O157 STEC. We believe it represents a new generation of tests for producers looking for increased sensitivity, accuracy and speed, with the added benefit of enumerating the bacterial load. Although we’ve had great interest in our technology over the past two years, now that we have AOAC certification, producers are able to purchase the RAPID-B platform to be used for a variety of applications, from incoming inventory analysis to end product testing.”

The RAPID-B platform offers results in seven hours or less, which is of great significance when comparing it to other diagnostic testing platforms that take 24 hours or more to produce results. These benefits are both economically significant and potentially life-saving. After almost eight years in development with National Center for Toxicological Research, Vivione is excited to finally bring these tests to market with AOAC certification. The AOAC certification is the premiere standard for the food industry, particularly the beef industry. Food producers look for the AOAC standard when selecting new platforms and bacterial contamination tests.

Achieving this milestone, Vivione’s RAPID-B E. coli O157 and Non O157 STEC tests are positioned to become one of the “go-to” tests used within the food industry. More importantly, these tests provide producers with something that they have not had access to prior to today: a test that can deliver increased sensitivity, while also significantly reducing the time needed to receive clear test results. The ability to undertake and report upon a test, beginning with the receipt and preparation of the sample through to the final analysis, in seven hours or less instead of the customary 24, stands to allow food producers to get their products to market faster while reducing potential recall risk.

About Vivione

Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B platform; an integrated platform of hardware, software and reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in key food & water safety, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B platform, the anticipated benefits of receiving AOAC certification and Vivione’s business and growth strategy. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Rate this press release
3 stars
v
Usefulness

Clarity

Credibility
Add to favourites icon Add to favourites